Biotechnology company Immunome Inc (NASDAQ: IMNM) announced on Monday that it has dosed the first patient in its Phase 1 trial of IM-1021, a ROR1-targeted antibody-drug conjugate (ADC).
This open-label, multicentre study aims to evaluate safety, tolerability, pharmacokinetics and preliminary anti-tumour activity in patients with advanced B-cell lymphomas and solid tumours.
IM-1021 incorporates Immunome's proprietary TOP1 inhibitor, HC74, designed to enhance targeted cancer therapy.
The company continues to advance its oncology pipeline, which includes varegacestat, a gamma secretase inhibitor in Phase 3 trials for desmoid tumours, and IM-3050, a FAP-targeted radioligand expected to enter clinical trials in 2025.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA